Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

NCT06851104 is registered in ClinicalTrials.gov with Guangxi Medical University as lead sponsor.

NCT NCT06851104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06851104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Lead sponsor
Guangxi Medical University
Phase
Phase 2
Overall status
Terminated
Start date
February 16, 2025
Completion date
December 31, 2025
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)